Inverness Medical Innovations and Epocal enter into distribution agreement

Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has entered into a distribution agreement with Epocal Inc. of Ottawa, Canada to distribute its epoc® Blood Analysis System for blood gas and electrolyte testing. The epoc (enterprise point of care) platform is a point-of-care analysis system which provides wireless bedside blood gas and electrolyte measurement testing solutions. Utilizing easy to use, low-cost disposable Smart- Cards(TM), the epoc System produces laboratory quality results in critical and acute care settings in about 30 seconds. The epoc system received FDA 510(k) clearance in 2006 for marketing in the US and anticipates receiving CE marking in 2010.

Under the five year agreement, Inverness will utilize its strong global sales force to promote the use of this point-of-care system co-exclusively with Epocal in all geographies worldwide, except for Japan, India, Bangladesh, Nepal, Bhutan and Sri Lanka. Inverness paid $20.0 million to Epocal in connection with the entry into the distribution agreement, which provides that Epocal will supply to Inverness, at no charge, all of Inverness' requirements for Epocal products and Inverness will pay to Epocal 50% of its revenues from the sale of Epocal products.

Separate from the distribution agreement, Inverness will work with Epocal in a collaboration to develop additional test menu content for the epoc testing platform, expanding Inverness' portfolio of test platforms in the point-of-care market. Inverness has also entered into a definitive agreement to acquire all of the issued and outstanding equity securities of Epocal for a total potential purchase price of up to $255 million, including a base purchase price of up to $172.5 million if Epocal achieves certain gross margin and other financial milestones on or prior to October 31, 2014, plus additional payments of up to $82.5 million if Epocal achieves certain other milestones relating to its gross margin and product development efforts on or prior to this date. The acquisition will also be subject to other closing conditions, including the receipt of any required antitrust or other approvals.

"The epoc platform, with its innovative blood gas and electrolyte solution, represents an exciting compliment in cardiology and emergency rooms to our Triage platform. Epocal's innovative test system and wireless connectivity solution set a new standard for the capability associated with point-of-care test offerings and an expandable platform onto which to introduce additional testing parameters for many years to come. Inverness will work closely with Epocal to develop new content for this state-of-the-art system for point-of-care testing," said Inverness CEO Ron Zwanziger.

Imants Lauks, PhD, President and Founder of Epocal, Inc. said today of the announcement: "The strategic partnership with Inverness, the world's leading provider of point-of-care testing, represents a significant milestone achievement for our company. This collaborative agreement expands the distribution and accelerates the market uptake of the best in class epoc System on a global scale."

SOURCE Inverness Medical Innovations, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breathing New Life into Diagnostics: Plasmion's SICRIT® Technology